معرفی
Adam Lokman is a Postdoctoral Research Scientist in the Riley Group at the Department of Physiology, Anatomy and Genetics (DPAG), University of Oxford, investigating inflammatory cell roles in heart failure with reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). His work centers on cardiac remodeling mechanisms following injury to identify novel therapeutic targets for reducing heart failure morbidity and mortality.
Dr. Lokman's research spans cardiovascular immunology and pathophysiology, with emphasis on how chronic inflammation drives disease progression in hypertrophic cardiomyopathy and other cardiac conditions. He utilizes experimental models to dissect molecular pathways involving immune cells, fibrosis, and genetic factors in heart failure development.
His recent publications reveal a cohesive focus on translational cardiovascular science, integrating immunological insights (regulatory T cells), genetic discoveries (ALPK3 variants), and physiological systems (lymphatic involvement) to address heart failure complexity. This multidisciplinary approach bridges basic mechanisms with potential clinical applications in cardioprotection.
As part of the Riley Group at DPAG—a department ranked #1 globally for Anatomy & Physiology—Dr. Lokman contributes to Oxford's mission of connecting discovery science with translational medicine in cardiovascular research, operating within a collaborative environment dedicated to advancing heart disease understanding.
